Fundz

Watching ImmunityBio, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

ImmunityBio, Inc.

nantkwest.com
Filed: Aug 4, 2026San Diego, CACIK: 0001326110Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

ImmunityBio announced Q2 2026 financial results and a business update on August 4, 2026, providing investors with an overview of the company's operational and financial position as of June 30, 2026.

Key Takeaways

Company released Q2 2026 financial results covering the three and six months ended June 30, 2026

Business update includes operational insights and financial position assessment as of mid-year 2026

2 more takeaways

Filing Overview

Form Type8-K
Filing DateAug 4, 2026
Item2.02
CategoryFinancial Results
CIK0001326110
Accession #ibrx-20260804
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings

ImmunityBio, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.